Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

In relation to the cost involved in changing form non-heat-treated to heat-treated material in the northern region, there was an argument as to whether people who were HIV antibody positive should continue to receive contaminated material.

  • Read more about In relation to the cost involved in changing form non-heat-treated to heat-treated material in the northern region, there was an argument as to whether people who were HIV antibody positive should continue to receive contaminated material.

Dr Rotblat delayed reporting Dr David Whitmore's HTLV-3 positive patient because Dr Whitmore had asked for confidentiality regarding the patient while he investigated the patient's lifestyle.

  • Read more about Dr Rotblat delayed reporting Dr David Whitmore's HTLV-3 positive patient because Dr Whitmore had asked for confidentiality regarding the patient while he investigated the patient's lifestyle.

Dr Peter Jones wrote to the Committee on Safety of Medicines setting out his argument for Armour materials to be withheld.

  • Read more about Dr Peter Jones wrote to the Committee on Safety of Medicines setting out his argument for Armour materials to be withheld.

Armour Pharmaceutical Company Limited in the UK was incorporated in 1959. It had several changes in name and parent company and was dissolved in 2010.

  • Read more about Armour Pharmaceutical Company Limited in the UK was incorporated in 1959. It had several changes in name and parent company and was dissolved in 2010.

The Northern Regional Health Authority's position on funding additional cost was yet to be declared.

  • Read more about The Northern Regional Health Authority's position on funding additional cost was yet to be declared.

Contrary to the findings of the Krever Inquiry, Justice Benotto, in a subsequent Canadian criminal case in 2007, found that it would have been unreasonable and irresponsible for Armour to have thrust Prince's studies into the community in a time of great uncertainty.

  • Read more about Contrary to the findings of the Krever Inquiry, Justice Benotto, in a subsequent Canadian criminal case in 2007, found that it would have been unreasonable and irresponsible for Armour to have thrust Prince's studies into the community in a time of great uncertainty.

The Krever Inquiry found that Armour should have informed the Canadian Bureau of Biologics about Dr Prince's findings, but chose not to.

  • Read more about The Krever Inquiry found that Armour should have informed the Canadian Bureau of Biologics about Dr Prince's findings, but chose not to.

Dr Brian Colvin thought that it would be more problematic if the heat-treated commercial products turned out to be unsafe from HIV.

  • Read more about Dr Brian Colvin thought that it would be more problematic if the heat-treated commercial products turned out to be unsafe from HIV.

The CBLA agreed to finance the trial of 8CRV.

  • Read more about The CBLA agreed to finance the trial of 8CRV.

Dr Jones apologised to the DHSS for making public his statement about heat-treated Factor 8 being unsafe.

  • Read more about Dr Jones apologised to the DHSS for making public his statement about heat-treated Factor 8 being unsafe.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 206
  • Page 207
  • Page 208
  • Page 209
  • Current page 210
  • Page 211
  • Page 212
  • Page 213
  • Page 214
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.